117 related articles for article (PubMed ID: 34908241)
1. B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab.
Jinich S; Schultz K; Jannat-Khah D; Spiera R
Arthritis Rheumatol; 2022 May; 74(5):776-782. PubMed ID: 34908241
[TBL] [Abstract][Full Text] [Related]
2. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab.
Schultz K; Jannat-Khah D; Spiera R
J Rheumatol; 2023 Mar; 50(3):420-425. PubMed ID: 36521910
[TBL] [Abstract][Full Text] [Related]
3. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
[TBL] [Abstract][Full Text] [Related]
4. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.
Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603
[TBL] [Abstract][Full Text] [Related]
5. Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.
Troldborg A; Thomsen MK; Bartels LE; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Mikkelsen S; Erikstrup C; Hauge EM; Ammitzbøll C
J Rheumatol; 2022 Jun; 49(6):644-649. PubMed ID: 35232803
[TBL] [Abstract][Full Text] [Related]
6. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L
J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999
[TBL] [Abstract][Full Text] [Related]
7. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.
Avouac J; Miceli-Richard C; Combier A; Steelandt A; Fogel O; Mariaggi AA; Meritet JF; Rozenberg F; Molto A; Allanore Y
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI163-SI168. PubMed ID: 34726701
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
Magliulo D; Wade SD; Kyttaris VC
Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
[TBL] [Abstract][Full Text] [Related]
10. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose.
Rose E; Magliulo D; Kyttaris VC
Clin Immunol; 2022 Dec; 245():109144. PubMed ID: 36220613
[TBL] [Abstract][Full Text] [Related]
15. [ANALYSIS OF FACTORS INVOLVED IN THE DEVELOPMENT OF HUMORAL RESPONSE TO VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH RHEUMATIC PATHOLOGY UNDER BIOLOGICAL TREATMENT.].
Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
Reumatol Clin; 2023 Jun; ():. PubMed ID: 37361903
[TBL] [Abstract][Full Text] [Related]
16. B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
Front Immunol; 2022; 13():822885. PubMed ID: 35514962
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease.
Simon D; Tascilar K; Fagni F; Schmidt K; Krönke G; Kleyer A; Ramming A; Schoenau V; Bohr D; Knitza J; Harrer T; Manger K; Manger B; Schett G
Ann Rheum Dis; 2022 Jul; 81(7):1023-1027. PubMed ID: 34819271
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study.
Shields AM; Venkatachalam S; Shafeek S; Paneesha S; Ford M; Sheeran T; Kelly M; Qureshi I; Salhan B; Karim F; De Silva N; Stones J; Lee S; Khawaja J; Kaudlay PK; Whitmill R; Kakepoto GN; Parry HM; Moss P; Faustini SE; Richter AG; Drayson MT; Basu S
Clin Exp Immunol; 2022 Jan; 207(1):3-10. PubMed ID: 35020852
[TBL] [Abstract][Full Text] [Related]
19. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.
van der Togt CJT; Ten Cate DF; van den Bemt BJF; Rahamat-Langendoen J; den Broeder N; den Broeder AA
Rheumatology (Oxford); 2023 Apr; 62(4):1627-1630. PubMed ID: 36000861
[TBL] [Abstract][Full Text] [Related]
20. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.
Haskin O; Ashkenazi-Hoffnung L; Ziv N; Borovitz Y; Dagan A; Levi S; Koren G; Hamdani G; Levi-Erez D; Landau D; Alfandary H
Transplantation; 2021 Nov; 105(11):e226-e233. PubMed ID: 34381004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
